Literature DB >> 28575416

Toxic drug-induced liver failure during therapy of rheumatoid arthritis with tocilizumab subcutaneously: a case report.

Friedrich Anger1, Armin Wiegering1, Johanna Wagner1, Johan Lock1, Johannes Baur1, Lukas Haug2, Marc Schmalzing3, Andreas Geier4, Stefan Löb1, Ingo Klein1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28575416     DOI： 10.1093/rheumatology/kex221

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  4 in total

Review 1.  Safety perspectives on presently considered drugs for the treatment of COVID-19.

Authors:  Sophie L Penman; Robyn T Kiy; Rebecca L Jensen; Christopher Beoku-Betts; Ana Alfirevic; David Back; Saye H Khoo; Andrew Owen; Munir Pirmohamed; B Kevin Park; Xiaoli Meng; Christopher E Goldring; Amy E Chadwick
Journal:  Br J Pharmacol       Date:  2020-08-13       Impact factor: 8.739

Review 2.  Biologic and Checkpoint Inhibitor-Induced Liver Injury: A Systematic Literature Review.

Authors:  Parth Shah; Vinay Sundaram; Einar Björnsson
Journal:  Hepatol Commun       Date:  2020-01-02

3.  Fulminant Liver Failure due to Hepatitis B Reactivation During Treatment With Tocilizumab.

Authors:  Milan J Sonneveld; S Darwish Murad; A A van der Eijk; R A de Man
Journal:  ACG Case Rep J       Date:  2019-12-09

Review 4.  Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic.

Authors:  Tobias Boettler; Thomas Marjot; Philip N Newsome; Mario U Mondelli; Mojca Maticic; Elisa Cordero; Rajiv Jalan; Richard Moreau; Markus Cornberg; Thomas Berg
Journal:  JHEP Rep       Date:  2020-08-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.